Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2012 and based in the United States, Decheng Capital is a global investment firm focused on the life sciences sector. The firm manages over $2 billion in assets and collaborates with entrepreneurs and scientists to support early-stage life science companies and growth-stage healthcare companies.
Decheng Capital invests in early-stage life science companies and growth-stage healthcare companies, targeting revolutionary technologies. The firm participates in funding rounds from pre-seed to growth equity, aiming to capitalize on opportunities in the rapidly growing healthcare industry.
Notable portfolio companies include Aardvark Therapeutics, which raised $85 million in Series C financing; Regeneron, which signed a $100 million gene editing deal; and Merck, which acquired Prometheus Biosciences for $10.8 billion. Other significant investments include Cellares, which secured $255 million in Series C funding, and Upstream Bio, which announced $200 million in Series B financing.
Submit your pitch through their form at decheng.com.
Decheng Capital invests across various stages, including pre-seed, seed, seed-plus, Series A, Series B, and growth equity.
The firm specializes in the life sciences sector, particularly early-stage life science companies and growth-stage healthcare companies.
Yes, Decheng Capital often leads funding rounds, particularly in early-stage investments within the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.